The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 11, 2017
Filed:
Aug. 31, 2015
Applicant:
Regentis Biomaterials Ltd., Or-Akiva, IL;
Inventors:
Dror Seliktar, Haifa, IL;
Liora Almany, Atlit, IL;
Assignee:
Regentis Biomaterials Ltd., Or-Akiva, IL;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/36 (2006.01); A61K 47/48 (2006.01); A61L 24/10 (2006.01); A61L 27/18 (2006.01); A61L 27/22 (2006.01); A61L 27/24 (2006.01); A61L 27/38 (2006.01); A61L 27/52 (2006.01); C07K 14/75 (2006.01); C12N 5/00 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 35/34 (2015.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/363 (2013.01); A61K 9/0024 (2013.01); A61K 9/06 (2013.01); A61K 35/34 (2013.01); A61K 47/48215 (2013.01); A61K 47/48292 (2013.01); A61K 47/48784 (2013.01); A61L 24/106 (2013.01); A61L 27/18 (2013.01); A61L 27/225 (2013.01); A61L 27/227 (2013.01); A61L 27/24 (2013.01); A61L 27/38 (2013.01); A61L 27/52 (2013.01); C07K 14/75 (2013.01); C12N 5/0068 (2013.01); A61K 38/00 (2013.01); C12N 2533/30 (2013.01); C12N 2533/40 (2013.01); C12N 2533/50 (2013.01); C12N 2533/52 (2013.01); C12N 2533/54 (2013.01);
Abstract
A method of treating a disorder characterized by tissue damage is provided. The method comprising providing to a subject in need-thereof a composition which comprises a synthetic polymer attached to denatured fibrinogen or a therapeutic portion of the fibrinogen, the composition being formulated for releasing the therapeutic portion of the fibrinogen in a pharmacokinetically regulated manner, thereby treating the disorder characterized by tissue damage or malformation.